Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adagio Medical HoldingsADGM -5.09%10 EV-to-EBITDA is -1.29 as of Aug. 26, 2026. GuruFocus rates ADGM with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 521 Medical Devices & Instruments companies, Adagio Medical Holdings ranks worse than 191938.39% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Adagio Medical Holdings's enterprise value is $29.86 Mil.
Adagio Medical Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-23.19 Mil. Therefore, Adagio Medical Holdings's EV-to-EBITDA for today is -1.29.
The historical rank and industry rank for Adagio Medical Holdings's EV-to-EBITDA or its related term are showing as below:
ADGM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.19 Med: -1.77 Max: -0.05
Current: -1.29
During the past 5 years, the highest EV-to-EBITDA of Adagio Medical Holdings was -0.05. The lowest was -3.19. And the median was -1.77.
ADGM's EV-to-EBITDA is ranked worse than 100% of 521
companies
in the Medical Devices & Instruments industry
Industry Median: 14.67
vs ADGM: -1.29
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Adagio Medical Holdings (NAS:ADGM) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Adagio Medical Holdings's PE Ratio (TTM) for today is calculated as:
Adagio Medical Holdings's share price for today is $0.522.
Adagio Medical Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.480.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Adagio Medical Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adagio Medical Holdings EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Adagio Medical Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Adagio Medical Holdings's EV-to-EBITDA falls into.
Adagio Medical Holdings's current Enterprise Value is $29.86 Mil.
Adagio Medical Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adagio Medical Holdings (ADGM) has a EV-to-EBITDA of -1.29 as of Aug. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Adagio Medical Holdings. According to the industry distribution chart, Adagio Medical Holdings ranks #999999 out of 521 companies in the Medical Devices & Instruments industry.
Is Adagio Medical Holdings' EV-to-EBITDA too high?
Adagio Medical Holdings' current EV-to-EBITDA is -1.29. Based on the distribution chart, Adagio Medical Holdings ranks #999999 out of 521 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Adagio Medical Holdings has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Adagio Medical Holdings' EV-to-EBITDA compare to NXL and ICCM?
According to the Medical Devices & Instruments industry distribution chart, Adagio Medical Holdings ranks #999999 out of 521 companies for EV-to-EBITDA. This places Adagio Medical Holdings in the lower half of its industry. The industry median EV-to-EBITDA is 14.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.67, based on 521 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Adagio Medical Holdings. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adagio Medical Holdings's current EV-to-EBITDA is -1.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adagio Medical Holdings stock overvalued right now?
Adagio Medical Holdings (ADGM) has a current EV-to-EBITDA of -1.29. The current EV-to-EBITDA is -1.29. Adagio Medical Holdings' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Adagio Medical Holdings (ADGM), the current EV-to-EBITDA is -1.29 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adagio Medical Holdings Inc is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias with its proprietary, catheter-based Ultra-Low Temperature Ablation (ULTA) technology. UTLA is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The company is currently focused on the treatment of ventricular tachycardia (VT), a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart's lower chambers, or ventricles. The company has one reportable segment.
10GF Score
Get the complete analysis for ADGM
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADGM has been successfully added to your 
